Victoria has once again been recognised as a global leader in advanced pharmaceutical manufacturing, with CSL’s fractionation facility named the Overall Winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE).
The award highlights Melbourne’s world-class capability to design, build and operate compliant, sustainable and highly innovative pharmaceutical manufacturing facilities — reinforcing Victoria’s position as a destination of choice for global companies investing in health and life sciences.
A next-generation manufacturing facility setting new global benchmarks
Located in Broadmeadows, CSL’s facility blends Pharma 4.0™ principles with sustainable design to transform plasma fractionation and production.
Built to increase access to plasma-derived therapies for people with immunodeficiencies, neurological conditions and severe burns, the facility features:
- Advanced automation and robotics
- Real-time production monitoring
- Digital twin infrastructure
- A hybrid and modular manufacturing platform
- Fully paperless execution and continuous improvement systems
These innovations have increased plasma processing capacity nine-fold, enabling CSL to process more than 9 million litres annually, improve yields, and ultimately reach more patients around the world.
Proof of Victoria’s global competitiveness
CSL’s win is a powerful signal to global investors that Victoria offers the infrastructure, talent and innovation required to lead in biomanufacturing.
- Victoria accounts for more than 40% of Australia’s pharmaceutical manufacturing output.
- Global biotech firms have invested over $3 billion in Victoria in the past five years.
- Melbourne delivers 60% of Australia’s pharmaceutical exports and is the country’s largest biotech ecosystem.
- The state is home to more than 70% of Australia’s top pharmaceutical and medtech companies, supported by 90,000 life science professionals — the largest talent base in the nation.
Victoria also offers companies streamlined clinical trial processes, globally connected biomedical precincts, and one of the most established and trusted regulatory environments in the Asia-Pacific.
A proven location for end-to-end pharmaceutical innovation
In Victoria, companies can research, trial, manufacture and export pharmaceutical products from one of the most sophisticated biomedical ecosystems in the world.
This includes the Melbourne Biomedical Precinct in Parkville and more than 22 globally recognised research institutes — a powerful cluster driving advances from mRNA to regenerative medicine.
Ready to invest in a globally trusted location?
Explore medtech and pharma opportunities.
